Successful multidisciplinary therapy for a patient with liver metastasis from ascending colon adenocarcinoma: A case report and review of literature
暂无分享,去创建一个
Hua-Wei Chen | Nan Jiang | W. Luo | Xiaofang Tan | Juan-Juan Li | Zheng Wang | Shuai Wang
[1] A. Jemal,et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries , 2021, CA: a cancer journal for clinicians.
[2] P. Lai,et al. Comparison of long-term survival outcome after curative hepatectomy between selected non-colorectal and colorectal liver metastases patients: A propensity score matching analysis. , 2020, Asian journal of surgery.
[3] F. Arias,et al. Stereotactic body radiation therapy for liver metastasis from colorectal cancer: size matters , 2020, Clinical and Translational Oncology.
[4] A. Jemal,et al. Colorectal cancer statistics, 2020 , 2020, CA: a cancer journal for clinicians.
[5] M. Bartels,et al. Current Treatment of Colorectal Liver Metastasis as a Chronic Disease , 2019, AntiCancer Research.
[6] A. Terahara,et al. [Five-Year Local Control by Stereotactic Body Radiation Therapy(SBRT)for Liver Metastasis from Colorectal Cancer-A Case Report]. , 2019, Gan to kagaku ryoho. Cancer & chemotherapy.
[7] M. Ychou,et al. Two‐stage hepatectomy for colorectal liver metastases: Pathologic response to preoperative chemotherapy is associated with second‐stage completion and longer survival☆ , 2019, Surgery.
[8] Y. Liu,et al. Comparison of efficacy and toxicity of bevacizumab, endostar and apatinib in transgenic and human lung cancer xenograftzebrafish model , 2018, Scientific Reports.
[9] W. Ceelen,et al. The impact of surgical resection of the primary tumor on the development of synchronous colorectal liver metastasis: a systematic review , 2018, Acta chirurgica Belgica.
[10] D. Richel,et al. Radiofrequency and Microwave Ablation Compared to Systemic Chemotherapy and to Partial Hepatectomy in the Treatment of Colorectal Liver Metastases: A Systematic Review and Meta-Analysis , 2018, CardioVascular and Interventional Radiology.
[11] D. Levi,et al. A Complete Pathological Response to Pembrolizumab following ex vivo Liver Resection in a Patient with Colorectal Liver Metastases , 2018, Chemotherapy.
[12] S. Truant,et al. Repeated Resections of Hepatic and Pulmonary Metastases from Colorectal Cancer Provide Long-Term Survival , 2018, World Journal of Surgery.
[13] Jong Hoon Kim,et al. Local Control Outcomes Using Stereotactic Body Radiation Therapy for Liver Metastases From Colorectal Cancer. , 2017, International journal of radiation oncology, biology, physics.
[14] L. Qin,et al. Recombined human endostatin (Endostar) enhances cisplatin delivery and potentiates chemotherapy by decompressing colorectal cancer vessels. , 2017, International journal of clinical and experimental pathology.
[15] Jeffrey W. Clark,et al. Prognostic Significance of Surgical Margin Size After Neoadjuvant FOLFOX and/or FOLFIRI for Colorectal Liver Metastases , 2017, Journal of Gastrointestinal Surgery.
[16] W. Chapman,et al. Time-to-Surgery and Survival Outcomes in Resectable Colorectal Liver Metastases: A Multi-Institutional Evaluation. , 2016, Journal of the American College of Surgeons.
[17] Chong Zhao,et al. The efficacy and safety of Endostar combined with chemoradiotherapy for patients with advanced, locally recurrent nasopharyngeal carcinoma , 2015, Oncotarget.
[18] B. Vogelstein,et al. PD-1 blockade in tumors with mismatch repair deficiency. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[19] Yin Zhang,et al. Endostar combined with irinotecan/calcium folinate/5-fluorouracil (FOLFIRI) for treating advanced colorectal cancer: A clinical study , 2015, Journal of chemotherapy.
[20] H. Ohdan,et al. Successful treatment of conversion chemotherapy for initially unresectable synchronous colorectal liver metastasis. , 2015, World journal of gastroenterology.
[21] S. Zhang,et al. Endostar in combination with modified FOLFOX6 as an initial therapy in advanced colorectal cancer patients: a phase I clinical trial , 2015, Cancer Chemotherapy and Pharmacology.
[22] D. Malka,et al. Place of hepatic intra-arterial chemotherapy in the treatment of colorectal liver metastases. , 2014, Journal of visceral surgery.
[23] V. Catalano,et al. Chemoembolization in colorectal liver metastases: the rebirth. , 2014, Anticancer research.
[24] K. Muro,et al. A Phase II Clinical Study of mFOLFOX6 Plus Bevacizumab as First-line Therapy for Japanese Advanced/Recurrent Colorectal Cancer Patients , 2013, Japanese journal of clinical oncology.
[25] Yutong He,et al. Recombinant Human Endostatin Endostar Inhibits Tumor Growth and Metastasis in a Mouse Xenograft Model of Colon Cancer , 2011, Pathology & Oncology Research.
[26] F. Saliba,et al. Impact of Expanding Criteria for Resectability of Colorectal Metastases on Short- and Long-Term Outcomes After Hepatic Resection , 2011, Annals of surgery.
[27] Yang Zhang,et al. A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy of Paclitaxel-Carboplatin Alone or with Endostar for Advanced Non-small Cell Lung Cancer , 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[28] Thomas Seufferlein,et al. Targeted treatments in colorectal cancer: state of the art and future perspectives , 2010, Gut.
[29] Rong-cheng Luo,et al. [Short-term therapeutic effect and safety of endostar combined with XELIRI regimen in the treatment of advanced colorectal cancer]. , 2010, Nan fang yi ke da xue xue bao = Journal of Southern Medical University.
[30] Pornpimol Charoentong,et al. Coordination of intratumoral immune reaction and human colorectal cancer recurrence. , 2009, Cancer research.
[31] Y. Guan,et al. Epidermal growth factor receptor antibody plus recombinant human endostatin in treatment of hepatic metastases after remnant gastric cancer resection. , 2007, World journal of gastroenterology.
[32] Na Lu,et al. Endostar, a novel recombinant human endostatin, exerts antiangiogenic effect via blocking VEGF-induced tyrosine phosphorylation of KDR/Flk-1 of endothelial cells. , 2007, Biochemical and biophysical research communications.
[33] D. Mavroudis,et al. Front-line Bevacizumab in combination with Oxaliplatin, Leucovorin and 5-Fluorouracil (FOLFOX) in patients with metastatic colorectal cancer: a multicenter phase II study , 2007, BMC Cancer.
[34] J. Folkman,et al. Antiangiogenesis in cancer therapy--endostatin and its mechanisms of action. , 2006, Experimental cell research.
[35] Robert D Timmerman,et al. A phase I trial of stereotactic body radiation therapy (SBRT) for liver metastases. , 2005, International journal of radiation oncology, biology, physics.
[36] J. Folkman. Tumor angiogenesis: therapeutic implications. , 1971, The New England journal of medicine.
[37] Zhigang Zhang,et al. Analysis on efficacy and safety of TACE in combination with RFA and MWA in the treatment of middle and large primary hepatic carcinoma. , 2019, Journal of B.U.ON. : official journal of the Balkan Union of Oncology.
[38] Xin-en Huang,et al. Clinical observation of Endostar® combined with chemotherapy in advanced colorectal cancer patients. , 2011, Asian Pacific journal of cancer prevention : APJCP.
[39] C. von Kalle,et al. Prospective, randomized, double-blind, multi-center, Phase III clinical study on transarterial chemoembolization (TACE) combined with Sorafenib®versus TACE plus placebo in patients with hepatocellular cancer before liver transplantation – HeiLivCa [ISRCTN24081794] , 2008, BMC Cancer.
[40] M. P. Tristan D. Yan BSc,et al. Systematic Review on Safety and Efficacy of Repeat Hepatectomy for Recurrent Liver Metastases from Colorectal Carcinoma , 2007, Annals of Surgical Oncology.